2021
10 | Submission of Clinical trial Phase 3 application to MFDS |
05 | Completion of Clinical trial Phase 1/2 |
02 | Initiation of Clinical trial Phase 2 |
01 | Completion of Clinical trial Phase 1 |
2020
12 | Initiation of Clinical trial Phase 1 |
08 | Approved for Authorization of Export by MFDS |
07 | Approved for GMP and Clinical trial Phase 1 by MFDS |
06 | Scheduled to inspection for GMP & Authorization for Export |
04 | Submission of Clinical trial application to MFDS |
03 | Completion of clinical trial production |
2019
11 | Completion of pre-clinical study |
10 | Approved for drug manufacturing by MFDS |
06 | CPhI China 2019 - Exhibitor |
04 | Completion of Plant |
02 | Pre-clinical trial product & Start pro-clinical study(Feb. 15) |
Issued new shares(44million) |
2018
12 | Process development for Pre-clinical trial product |
Issued new shares(19million) | |
11 | Characterization of Botulinum Toxin |
10 | Contracted with Pre-Clinical Trial CRO (Biotoxtech.co.Ltd) |
2017
02 | Animal experimental facilities registration |
01 | Completed reporting of high-risk pathogen treatment research facility (No. KCDC-17-2-01) |
Botulinum movement and retention report Korea Centers for Disease Control and Prevention (Management No.: 4-026-CBB-CO-040) |
2016
12 | Extension of expansion of R&D Center (in Hyangnam-eup, Hwaseong-si, Gyeonggi-do) |
08 | Acquire license of medical device manufacturing (for export) |
Acquire license of medical device manufacturing | |
07 | Took over MEDICA Korea Co., Ltd. (USD 33million) |
04 | Established Seoul office (Diplomatic center) |
Transferred PROTOX HQ. (Anseong GMP Factory) | |
03 | Took over Anseong GMP factory (10,000m2) as subsidiary of DSK |
2015
12 | Authorized venture company (Korea Technology Finance Corporation) |
11 | Established PROTOX CO., LTD. |
96, Jeyakgongdan 4-gil, Sangsin-ri, Hyangnam-eup, Hwaseong-si, Gyeonggi-do | TEL. 1522-4140 | FAX. +82-2-572-9011
COPYRIGHT © 2019 Protox. All rights reserved